UPDATE: Malecare Advocacy Restores CDC Prostate Cancer Funding
UPDATE June 9, 2016 The Senate Appropriations Committee voted to approve its FY17 Labor-HHS Appropriations bill earlier today, with only one senator, Bill Cassidy (R-LA), voting against the bill. Funding for the Centers for Disease [...]
UK’s NICE Reverses Itself and Now Recommends Zytiga To Treat Men Before Chemotherapy
In a sudden reversal of its prior opinion the UK's National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Janssen’s Zytiga (abiraterone) to treat advanced prostate cancer before chemotherapy. Its prior [...]
Men With Castrate Resistant Prostate Cancer Can Experience A PSA Flare When Starting Docetaxel Chemotherapy
The PSA flare phenomenon when first starting chemotherapy with docetaxel has been noted by many clinicians. To evaluate this flare in men with castrate resistant prostate cancer treated with docetaxel, researchers retrospectively evaluated the charts [...]
Comparing (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline PET/CT in Prostate Cancer Relapse
There has been a lot of hype and confusion about what is the best contrast for prostate cancer PET/CT scans. The two newest contrasts; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline both have their supporters and their [...]
Xtandi Vs Zytiga
The phase III trials for both Xtandi and Zytiga were similar. Both trials investigated men who progressed or died against placebo. Only 14% of men taking Xtandi during the trial progressed or died compared [...]
PSA Decline After 4 Weeks of Abiraterone Suggests Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer
Since we have many new treatments for men with castrate resistant metastatic prostate cancer (mCRPC) (advanced prostate cancer) we need to develop earlier indicators of when a treatment might or might not be successful. A [...]